| Document |
Document Title |
|
WO/2023/078807A1 |
The present invention relates to a pharmaceutical composition comprising a class Ila HDAC inhibitor characterised by a trifluoromethyloxadiazole group and/or 5-Aza-2-deoxycytidine for use in treating myopathy.
|
|
WO/2023/080157A1 |
The present invention pertains to a therapeutic or prophylactic for HTLV-1-associated myelopathy (HAM), said therapeutic or prophylactic including a substance that inhibit the activity of the MAPK signaling pathway in which mitogen-activ...
|
|
WO/2023/081676A1 |
The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an ...
|
|
WO/2023/080753A1 |
The present invention relates to a pharmaceutical kit for parenteral co-administration, comprising a first formulation comprising a first drug, and a second formulation comprising a second drug and a parenteral drug delivery system. Due ...
|
|
WO/2023/075122A1 |
The present invention relates to a novel use of AFAP1 antisense RNA1 (AFAP1-AS1) and MLK7 antisense RNA1 (MLK7-AS1) as targets for treatment and metastasis inhibition of colorectal cancer, and, more particularly, to a kit for diagnosing ...
|
|
WO/2023/072240A1 |
Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.
|
|
WO/2023/072872A1 |
The present invention relates to a tadalafil oral suspension comprising 0.01-5 % w/v of tadalafil, a cyclodextrin, coprocessed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as vehicle. The suspensio...
|
|
WO/2023/077172A2 |
|
|
WO/2023/073526A1 |
Provided herein are methods for improving delivery of a pharmaceutical composition to the central nervous system of a subject in need thereof, the method comprising administering to the subject an agent that enhances glymphatic influx in...
|
|
WO/2023/076243A1 |
The present invention relates generally to methods for reducing, minimizing, preventing, ameliorating, or eliminating one or more side effects associated with administration of an apical sodium-dependent bile acid transporter inhibitor (...
|
|
WO/2023/076329A1 |
The present invention relates to compositions comprising resolvins and their use in methods of treating cancer.
|
|
WO/2023/074794A1 |
The present disclosure provides a novel treatment for diabetes. The present disclosure provides a treatment for diabetes, in which blood sugar control and HDAC adjustment are combined. According to one embodiment, the present disclosure ...
|
|
WO/2023/076765A1 |
This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer thera...
|
|
WO/2023/076404A1 |
Provided is a method for treating systemic lupus erythematosus (SLE) in a patient in need thereof comprising administering a therapeutically effective amount of a leucine-rich repeat kinase 2 (LRRK2) inhibitor.
|
|
WO/2023/076620A1 |
Described herein are hydrogel capsule compositions which comprise a population of hydrogel capsules and a pharmaceutically acceptable solution. The hydrogel capsules in the population comprise a hydrogel-forming polymer and encapsulate a...
|
|
WO/2023/073134A2 |
The present invention concern endothelin receptor antagonists for use in the treatment or the prevention of muscle fibrosis.
|
|
WO/2023/076556A1 |
The present invention provides compounds, compositions thereof, and processes for preparing same.
|
|
WO/2023/072010A1 |
The use of a PPAR agonist in the preparation of a drug for treating acute myeloid leukemia.
|
|
WO/2023/074869A1 |
The present invention addresses the problem of providing a method for evaluating the risk of stomach cancer onset. Specifically, the present invention is a method for evaluating the risk of stomach cancer onset, wherein the risk of stoma...
|
|
WO/2023/071859A1 |
The present invention relates to the technical field of medications, and particularly relates to a pharmaceutical composition capable of effectively preventing an SN triple bond structure compound from being deactivated, and enhancing ta...
|
|
WO/2023/076332A1 |
The present invention relates to the development of a subcutaneous formulation of a combination of nucleoside, Gemcitabine and Zebularine. For immediate release formulation gemcitabine and zebularine may be formulated in saline solution....
|
|
WO/2023/076096A1 |
The invention provides novel approaches to the prevention and treatment of the respiratory or non-respiratory infections and effects of mild to severe cytokine storms including multiorgan effects as well as the reduction in mortality. Mo...
|
|
WO/2023/067138A1 |
The present invention relates to novel uses of gamma delta T-cell activating antibodies, in particular uses of such antibodies in patients that are also being treated, or have recently been treated, with aminobisphosphonates, or other in...
|
|
WO/2023/068858A1 |
This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or...
|
|
WO/2023/065550A1 |
The present invention provides a polydisulfide polypeptide nanoparticle, which is a nanoparticle formed by assembling a disulfide heterocyclic compound and a polypeptide drug. The disulfide heterocyclic compound has a structure as shown ...
|
|
WO/2023/068328A1 |
The purpose of the present invention is to discover and provide a novel ubiquitin drug discovery technique whereby it becomes possible to induce a ubiquitin-proteasome system from a target peptide that is difficult to be ubiquitinated an...
|
|
WO/2023/068104A1 |
The present invention provides a medical agent improving antitumor effect.
|
|
WO/2023/067058A1 |
The invention relates generally to cancer treatments involving an epigenetic agent which promotes the effectiveness of a kinase inhibitor.
|
|
WO/2023/068404A1 |
The present invention relates to a method for providing information for selecting a treatment drug for an EML4-ALK-positive non-small cell lung cancer patient, and a composition for treating ALK inhibitor-resistant non-small cell lung ca...
|
|
WO/2023/068376A1 |
Provided is a pharmaceutical composition which is effective as an anti-cancer immunostimulating therapy. Said pharmaceutical composition has a compound set forth in general formula (I) or a salt thereof as an active ingredient {in the fo...
|
|
WO/2023/069152A1 |
The present invention includes methods for treating a proliferative disorder in a subject with mutated or constitutively active FLT3 in a subject relapsed/refractory to one or more prior tyrosine kinase inhibitors comprising: obtaining a...
|
|
WO/2023/068297A1 |
The present invention addresses the problem of providing a composition that is used in order to prevent or suppress refeeding syndrome. Provided as a solution to the problem is a composition that is used to prevent or suppress refeeding ...
|
|
WO/2023/068325A1 |
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nit...
|
|
WO/2023/067485A1 |
Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical compositio...
|
|
WO/2023/067483A1 |
The invention relates to a pharmaceutical combination comprising an MDM2 inhibitor, a BCL2 inhibitor and a hypomethylating agent. The present invention also relates to methods of treating haematological malignancies involving said combin...
|
|
WO/2023/068176A1 |
Provided are: a neuron proliferation promoting agent containing, as an active ingredient, an inhibitor of miR-191-5p or an expression inhibitor of miR-191-5p; a prophylactic or therapeutic agent for Alzheimer's disease or depression, the...
|
|
WO/2023/069037A1 |
The present invention relates to ophthalmic formulations for the treatment of presbyopia, dry eye disease and computer vision syndrome, and a method for preparing the same. The objective of the present invention is to treat symptoms caus...
|
|
WO/2023/068366A1 |
The present invention addresses mainly the problem of providing a novel composition or pharmaceutical that targets the mitochondrial network etc. and exhibits excellent anticancer activity while having a minimal effect on normal cells.ã€...
|
|
WO/2023/068226A1 |
The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said an...
|
|
WO/2023/067501A1 |
In one aspect, methods are provided for treating a human subject having or susceptible to mucositis, comprising administering to the human subject an effective amount of EC-18, thereby treating or preventing the mucositis.
|
|
WO/2023/065551A1 |
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic co...
|
|
WO/2023/061446A1 |
The present invention belongs to the field of medicine. Provided is a pharmaceutical composition for enhancing the anti-tumor effect of an EZH2 inhibitor. The pharmaceutical composition comprises an EZH2 inhibitor and a PPARα agonist, w...
|
|
WO/2023/063154A1 |
[Problem] To provide: a novel tracer drug for radioactive PET diagnosis that has high accumulation properties and retention properties at a tumor site, and an efficient production method (labeling synthesis method) of the tracer drug. [S...
|
|
WO/2023/063827A1 |
The invention relates to a bismuth containing composition for use in prophylaxis or treatment of an infection by Pseudomonas (P.) aeruginosa. The invention further relates to the concomitant use of a bismuth containing compound and an an...
|
|
WO/2023/063026A1 |
A problem addressed by the present invention is to provide an anti-MerTK antibody that has a tumor-suppressing effect and does not tend to cause ocular toxicity.　The present invention provides an antibody or a fragment thereof that bin...
|
|
WO/2023/062149A1 |
The present invention concerns a new method based on the combination of a particular osmotic swelling, an adapted and controlled plasma membrane lysis and removal, to produce said giant extracellular organelles vesicles, and use of said ...
|
|
WO/2023/063325A1 |
The purpose of the present invention is to provide therapeutic and preventive agents for COVID-19. The present invention provides a therapeutic or preventive composition for COVID-19, said composition containing an ADAM10 inhibitor. The ...
|
|
WO/2023/061457A1 |
Disclosed in the present invention are an antibody-drug conjugate, a pharmaceutical composition comprising the antibody-drug conjugate, and an application of the antibody-drug conjugate and the pharmaceutical composition in preparation o...
|
|
WO/2023/063400A1 |
Provided is a transgenic non-human animal enabling an analysis of an evaluation of proteasome function and activity on an individual basis. The present invention relates to a transgenic non-human animal and the like with an attenuated pr...
|
|
WO/2023/020212A9 |
Use of a DRD2 inhibitor in the preparation of a drug for treating diseases associated with liver fibrosis. In one embodiment, the DRD2 inhibitor is Fluphenazine (Flu) and a pharmaceutically acceptable salt thereof.
|
